Key result
Point-of-care BNP and NT-proBNP testing facilitates faster ER triage and real-time outpatient HF management.
Why the study?
Does point-of-care testing for natriuretic peptides improve diagnosis and management in patients with heart failure?
Does point-of-care testing for natriuretic peptides improve diagnosis and management in patients with heart failure?
Point-of-care testing for natriuretic peptides offers potential for faster triage in the emergency room and real-time management in outpatient settings for heart failure patients.
Heart failure is a leading cause of morbidity and mortality worldwide. The presenting symptoms of heart failure are often nonspecific. The diagnosis of heart failure has traditionally relied heavily upon clinical exam findings, which are often subjective and have low sensitivity. Efficient and rapid diagnosis of heart failure in the emergency room setting can reduce health care costs, hospital admission and ER visits, and improve patient care. Natriuretic peptides are objective biomarkers that can help with diagnosis, prognosis and management of heart failure. The most extensively studied and clinically utilized natriuretic peptides include brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP). Point-of-care testing in the emergency room setting can result in faster triage times. Point-of-care testing can also be utilized in the outpatient setting for real-time management of patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Iwaz et al. (2016) conducted a review in Heart failure. Point-of-care testing for natriuretic peptides was evaluated. Point-of-care testing for natriuretic peptides like BNP and NT-proBNP can facilitate faster triage in the emergency room and enable real-time management of heart failure in outpatient settings.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: